App Logo
menu

Menu

close
expand_more

AML Resources

expand_less
/
/
AML Clinical Trials

AML Clinical Trials

Here you will find articles that keep you up to date on the newest AML research that AML experts are recruiting for. AML research studies called clinical trials are all about drug development. Drugs must go through many phases of testing to receive FDA approval in order to be prescribed to patients by doctors. Joining a clinical trial for your AML has the potential to provide you with cutting-edge treatment that is not yet widely available to the general public.

 

In addition to drug development, AML research aims to answer important questions like "what is AML?", "what causes AML?", "is AML genetic?" and "how do we improve AML survival?"

 

There are over 300 AML research trials actively recruiting patients, which is more than any other leukemia. These articles will keep you informed on the latest clinical trials that are recruiting and the types of new drug therapies that are being studied for the treatment of AML. 

Article Category Image
List-tile-article

VOR33 Receives Fast Track Designation to Treat AML

VOR33, a cell therapy candidate intended to replace the standard of care in stem cell transplant, receives fast track designation from the FDA, making this therapy eligible for priority review and accelerated approval if certain conditions are met. This designation demonstrates the FDA's acknowledgment that this engineered stem cell product could fulfill a major unmet medical need for those with AML at a high risk of relapse.
List-tile-article

What’s New in AML Clinical Trials?

We want to keep you up to date on what's going on in AML research. Here is a compilation of the major research topics experts are exploring in 2021.
List-tile-article

Romyelocel-L: An Immune Cell Treatment Shown to Prevent Infections in AML Patients

Patients undergoing chemotherapy for AML are at a high risk for infection, which is the leading cause of complications during induction therapy. Romyelocel-L is a treatment of ready-made human immune cells that has been shown to prevent infections in patients treated for AML who have weakened immune systems, according to the results of a phase 2 trial published in the Journal of Clinical Oncology.
List-tile-article

The Komet-001 Trial is Open to Patients with Relapsed or Refractory AML who have NPM1 Mutations

Today, the first patient in the Phase 1b KOMET-001 trial was given KO-359, an oral investiagional drug candidate for patients with relapsed or refractory AML who have NPM1 mutations or KMT2A rearrangements. This trial is currently recruiting patients. You can check out the details on our clinicial trial finder by clicking the link at the end of this article.
List-tile-article

How to Find an AML Clinical Trial

Joining a clinical trial can you access to cutting edge medications that are not yet widely available. Here's what to consider when contemplating whether or not to join a clinical trial.

Get the latest thought leadership on AML delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for AML Newsletter" for AML news, life with AML stories, AML clinical trials, AML 101 articles and events with AML experts.

Thanks to our HealthTree Community for AML Sponsors:

Follow Us

facebook instagram twitter youtube

 

Terms of Use and Privacy Policy     Newsroom     About    Donations    Find an AML Specialist     Newsletter     Learn     Connect

 

Copyright © 2021 HealthTree Foundation. All Rights Reserved.

The HealthTree Foundation / HealthTree for AML is a qualified 501(c)(3) tax-exempt organization. Tax ID 45-5354811